Marstacimab (20, 50 and 100 nmol/L) decreases rotational thromboelastometry (ROTEM) corn trypsin (CT) of the whole blood that obtained from haemophilia participants[1].
Marstacimab (16 μg/mL) decreases the lag time and increases thrombin generation of human nonhemophilic plateletpoor plasma samples in vitro[2].
Marstacimab (16 μg/mL) increases the peak thrombin in both hemophilia A and hemophilia B plasma samples in vitro[2].
Marstacimab (0.5 mg/kg; i.v., once) does not affect the blood flow situation in mouse acute bleeding models[2].
References:
[1]. Patel-Hett S, et al. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia. 2019 Sep;25(5):797-806.
[2]. Pittman DD, et al. Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model. Res Pract Thromb Haemost. 2022 Mar 16;6(2):e12679.